Table 1.
Baseline characteristics according to GN subtype
| Characteristic | Primary GN Subtypes | Secondary GN Subtypes | Non-GN Comparator Groups | |||||
|---|---|---|---|---|---|---|---|---|
| FSGS | IgAN | MN | MPGN | LN | Vasculitis | DN | ADPKD | |
| n (% among GN types) | 34,330 (40.7) | 13,012 (15.4) | 7177 (8.5) | 5193 (6.2) | 16,463 (19.5) | 8126 (9.6) | 720,001 (n/a) | 36,272 (n/a) |
| Age, median (IQR), y | 51 (38–65) | 44 (33–57) | 59 (47–71) | 53 (41–65) | 39 (29–50) | 66 (54–75) | 63 (54–72) | 54 (47–64) |
| Sex, male | 61.6 | 67.6 | 66.0 | 60.4 | 18.2 | 52.4 | 52.2 | 54.0 |
| Race | ||||||||
| White | 59.0 | 75.1 | 69.5 | 74.5 | 43.4 | 88.8 | 64.9 | 82.0 |
| Black | 36.2 | 6.6 | 26.0 | 18.1 | 48.6 | 7.5 | 27.8 | 13.1 |
| Asian | 3.5 | 15.4 | 3.0 | 4.9 | 5.8 | 1.9 | 4.4 | 3.8 |
| Other | 1.4 | 2.9 | 1.5 | 2.4 | 2.1 | 1.8 | 2.8 | 1.0 |
| Hispanic ethnicity | 8.6 | 12.4 | 10.0 | 10.6 | 16.2 | 8.9 | 17.1 | 8.6 |
| Medicaid insured | 18.4 | 13.4 | 16.5 | 20.2 | 31.0 | 11.9 | 28.3 | 12.5 |
| ESRD therapy | ||||||||
| Hemodialysis | 78.4 | 70.1 | 82.0 | 80.9 | 85.5 | 91.6 | 91.4 | 70.5 |
| Peritoneal dialysis | 14.5 | 16.8 | 12.8 | 11.6 | 10.8 | 6.5 | 7.1 | 15.6 |
| Transplant | 6.1 | 11.9 | 4.2 | 6.3 | 3.1 | 1.5 | 0.9 | 12.7 |
| Missing | 1.0 | 1.3 | 1.0 | 1.2 | 0.7 | 0.4 | 0.6 | 1.2 |
| Geographic region | ||||||||
| Northeast | 20.0 | 19.6 | 20.4 | 20.9 | 16.1 | 19.3 | 16.8 | 19.7 |
| Midwest | 23.3 | 23.0 | 23.6 | 24.7 | 18.4 | 27.2 | 20.5 | 22.9 |
| South | 39.6 | 30.3 | 37.9 | 32.9 | 44.1 | 33.2 | 39.8 | 36.1 |
| West | 16.6 | 26.6 | 17.0 | 20.5 | 20.3 | 20.0 | 20.9 | 20.2 |
| Missing | 0.6 | 0.5 | 1.2 | 1.0 | 1.1 | 0.3 | 2.0 | 1.1 |
| Comorbidities | ||||||||
| Diabetes | 13.3 | 9.3 | 15.0 | 14.9 | 8.9 | 15.9 | 88.0 | 7.5 |
| Heart failure | 14.6 | 8.3 | 18.8 | 17.9 | 15.0 | 18.2 | 38.5 | 8.4 |
| Coronary heart disease | 12.2 | 6.5 | 15.2 | 10.6 | 6.3 | 14.5 | 28.1 | 9.6 |
| Cerebrovascular event | 4.1 | 2.4 | 5.7 | 4.2 | 5.2 | 5.3 | 10.5 | 4.3 |
| Hypertension | 78.5 | 79.1 | 78.3 | 77.7 | 75.1 | 67.3 | 81.1 | 79.8 |
| COPD | 5.7 | 2.7 | 7.2 | 6.8 | 2.4 | 10.2 | 7.6 | 3.5 |
| Current smoker | 7.4 | 4.8 | 7.2 | 8.5 | 4.2 | 4.4 | 4.7 | 5.8 |
| Cancer | 4.8 | 2.8 | 6.2 | 5.7 | 1.6 | 6.0 | 3.9 | 3.6 |
| PVD | 5.1 | 2.9 | 6.2 | 5.0 | 3.5 | 7.6 | 19.8 | 3.4 |
| Nonambulant | 1.6 | 0.9 | 2.6 | 2.2 | 2.4 | 3.5 | 6.6 | 1.0 |
| Laboratory measurements | ||||||||
| Albumin, g/dl | 3.3±0.8 | 3.5±0.7 | 2.9±0.9 | 3.0±0.8 | 2.9±0.8 | 3.0±0.7 | 3.1±0.7 | 3.8±0.6 |
| Albumin missing | 23.1 | 22.5 | 22.3 | 22.3 | 23.6 | 23.2 | 25.5 | 23.4 |
| Hemoglobin, g/dl | 10.1±1.8 | 10.1±1.9 | 10.0±1.8 | 9.9±1.8 | 9.4±1.8 | 9.6±1.7 | 9.9±1.6 | 10.5±1.8 |
| Hemoglobin missing | 11.4 | 11.5 | 11.4 | 11.7 | 9.9 | 10.6 | 10.5 | 11.7 |
| Creatinine, mg/d | 8.4±4.2 | 8.4±4.0 | 7.7±3.8 | 7.4±3.7 | 7.4±3.5 | 7.5±3.6 | 6.3±2.8 | 7.6±3.3 |
| Creatinine missing | 2.0 | 1.5 | 1.6 | 1.8 | 1.4 | 1.1 | 1.2 | 1.4 |
| eGFR, ml/min per 1.73 m2 | 8.7±4.1 | 8.4±4.0 | 9.2±4.5 | 9.5±4.6 | 9.4±4.6 | 8.7±4.3 | 10.6±4.7 | 8.5±3.8 |
| eGFR missing | 2.6 | 2.1 | 2.6 | 2.9 | 2.5 | 1.7 | 2.2 | 2.0 |
Values are percentages, mean±SDs, or as otherwise indicated. IQR, interquartile range; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; eGFR, eGRF using the 4-variable Modification of Diet in Renal Disease formula; IgAN, IgA nephropathy; MN, membranous nephropathy; MPGN, membranoproliferative GN; LN, lupus nephritis; DN, diabetes-related ESRD; n/a, not applicable; ADPKD, autosomal dominant polycystic kidney disease.